Can gene editing drive out HIV and hepatitis viruses from inside cells?
By Cormac Sheridan,
Nature Biotechnology
| 10. 30. 2023
A gene-editing therapy based on CRISPR–Cas9 designed to eliminate HIV-1 infection has rekindled hopes among scientists that it may be possible to eradicate the virus and cure the infection. In an in vivo editing study in non-human primates conducted by scientists from Temple University and Excision BioTherapeutics, a single dose of a CRIPSR therapy excised the simian immunodeficiency virus (closely related to HIV-1) from the DNA of infected animals with no observable off-target effects or other safety problems. The equivalent human therapy, EBT-101, is undergoing a phase 1/2 clinical trial in people infected with HIV-1.
This CRISPR therapy is part of a wave of sophisticated genetic approaches targeting difficult-to-treat chronic infections (Table 1). In addition to gene editing, therapies, including antisense oligonucleotides, short interfering RNA (siRNA), gene therapy, therapeutic vaccines and chimeric antigen receptor (CAR)-T cell therapies, are being brought to bear on a range of pathogens, but most prominently on HIV-1 and chronic hepatitis B virus (HBV) infection.
Once a person is infected and after the acute stage resolves, these viruses can persist indefinitely — in CD4 T...
Related Articles
By Emily Mullin, Wired | 11.14.2023
In a small initial test in people, researchers have shown that a single infusion of a novel gene-editing treatment can reduce cholesterol, the fatty substance that clogs and hardens arteries over time.
The gene-editing treatment aims to permanently lower cholesterol...
By Carissa Wong, Nature | 11.16.2023
In a world first, the UK medicines regulator has approved a therapy that uses the CRISPR–Cas9 gene-editing tool as a treatment. The decision marks another high point for a biotechnology that has been lauded as revolutionary in the decade since...
By Emily Mullin, Wired | 11.16.2023
The first medical treatment that uses Crispr gene editing was authorized Thursday by the United Kingdom.
The one-time therapy, which will be sold under the brand name Casgevy, is for patients with sickle cell disease and a related blood disorder...
By Alexis Heng, UCA News | 11.13.2023
In recent years, Singapore has increasingly leveraged new reproductive technologies to overcome the country's rapidly aging demographics and dismal fertility rate, which hit a new low in 2022.
Hence, it would be timely for Singapore’s Bioethics Advisory Committee (BAC) to...